Ellen Hertz - Search Results

Year	Number of Results
2002	1
2013	1
2014	1
2015	1
2016	2
2019	1
2020	1
2021	1
2022	4
2023	4
2024	1

1

Targeting protein clearance pathways in GBA1-associated Parkinson disease.

Chen C, Hertz E, Chen Y, Sidransky E. Chen C, et al. Among authors: hertz e. Expert Opin Ther Targets. 2022 Dec;26(12):1031-1035. doi: 10.1080/14728222.2022.2166828. Epub 2023 Jan 12. Expert Opin Ther Targets. 2022. PMID: 36628605 Free PMC article. No abstract available.

2

Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease.

Paslawski W, Khosousi S, Hertz E, Markaki I, Boxer A, Svenningsson P. Paslawski W, et al. Among authors: hertz e. Transl Neurodegener. 2023 Sep 4;12(1):42. doi: 10.1186/s40035-023-00374-w. Transl Neurodegener. 2023. PMID: 37667404 Free PMC article.

3

Rapid-Onset Dystonia and Parkinsonism in a Patient With Gaucher Disease.

Hertz E, Lopez G, Lichtenberg J, Haubenberger D, Tayebi N, Hallett M, Sidransky E. Hertz E, et al. J Mov Disord. 2023 Sep;16(3):321-324. doi: 10.14802/jmd.23074. Epub 2023 Jun 13. J Mov Disord. 2023. PMID: 37309111 Free PMC article.

4

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism.

Furderer ML, Hertz E, Lopez GJ, Sidransky E. Furderer ML, et al. Among authors: hertz e. Int J Mol Sci. 2022 May 23;23(10):5842. doi: 10.3390/ijms23105842. Int J Mol Sci. 2022. PMID: 35628652 Free PMC article. Review.

5

Is Gauchian genotyping of GBA1 variants reliable?

Tayebi N, Lichtenberg J, Hertz E, Sidransky E. Tayebi N, et al. Among authors: hertz e. medRxiv [Preprint]. 2023 Oct 26:2023.10.26.23297627. doi: 10.1101/2023.10.26.23297627. medRxiv. 2023. PMID: 37986861 Free PMC article. Preprint.

6

New tools can propel research in lysosomal storage diseases.

Hertz E, Glasstetter LM, Chen Y, Sidransky E. Hertz E, et al. Mol Genet Metab. 2023 Dec;140(4):107729. doi: 10.1016/j.ymgme.2023.107729. Epub 2023 Nov 3. Mol Genet Metab. 2023. PMID: 37951057

7

Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels.

Te Vruchte D, Sturchio A, Priestman DA, Tsitsi P, Hertz E, Andréasson M, Markaki I, Wallom KL, Platt F, Svenningsson P. Te Vruchte D, et al. Among authors: hertz e. Mov Disord. 2022 Oct;37(10):2129-2134. doi: 10.1002/mds.29163. Epub 2022 Jul 25. Mov Disord. 2022. PMID: 35876461 Free PMC article.

8

Glucocerebrosidase variant T369M is not a risk factor for Parkinson's disease in Sweden.

Ran C, Brodin L, Gellhaar S, Westerlund M, Fardell C, Nissbrandt H, Söderkvist P, Sydow O, Markaki I, Hertz E, Wirdefeldt K, Svenningsson P. Ran C, et al. Among authors: hertz e. Neurosci Lett. 2022 Jul 27;784:136767. doi: 10.1016/j.neulet.2022.136767. Epub 2022 Jun 30. Neurosci Lett. 2022. PMID: 35779693 Free article.

9

GM1 Is Cytoprotective in GPR37-Expressing Cells and Downregulates Signaling.

Hertz E, Saarinen M, Svenningsson P. Hertz E, et al. Int J Mol Sci. 2021 Nov 27;22(23):12859. doi: 10.3390/ijms222312859. Int J Mol Sci. 2021. PMID: 34884663 Free PMC article.

10

Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease.

Markaki I, Bergström S, Tsitsi P, Remnestål J, Månberg A, Hertz E, Paslawski W, Sorjonen K, Uhlén M, Mangone G, Carvalho S, Rascol O, Meissner WG, Magnin E, Wüllner U, Corvol JC, Nilsson P, Svenningsson P. Markaki I, et al. Among authors: hertz e. Mov Disord. 2020 Nov;35(11):2101-2106. doi: 10.1002/mds.28192. Epub 2020 Aug 15. Mov Disord. 2020. PMID: 33179332

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

16 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year